Trial reportScientific reports2025
Prediction of antioxidant capacity, age, and sex on sleep impairment in patients with amyotrophic lateral sclerosis.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04654689 (Impact of the Combined Treatment of Curcumin and Resveratrol Liposomed Polyphenols With G04CB02 on the Clinical Improvement of ALS Patients), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of the Combined Treatment of Curcumin and Resveratrol Liposomed Polyphenols With G04CB02 on the Clinical Improvement of ALS Patients
Who cites it
1 citing paper in PubMed.
- Nocturnal hypoxemia mediates age-related sleep fragmentation in amyotrophic lateral sclerosis: a polysomnographic case-control study.Acta neurologica Belgica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterised by high levels of inflammation and oxidative stress, predominantly affecting males, particularly those between the ages of 50 and 65 years. It is characterised by progressive loss of motor neurones, leading to both motor and non-motor symptoms, such as sleep impairment, diagnosed in most patients, which adversely affects their quality of life. Therefore, this study aimed to determine the predictive role of antioxidant capacity, psychological distress, age, and sex on sleep impairment in an adult population of patients with ALS. A descriptive, quantitative, cross-sectional study was conducted using a sample of 74 patients diagnosed with bulbar or spinal ALS. To assess sleep disturbances in these patients, the Pittsburgh sleep quality index (PSQI), epworth sleepiness scale (ESS), and Insomnia severity index were used. Additionally, plasma antioxidant capacity was analysed using the total antioxidant capacity (TEAC), Cupric Ion reducing antioxidant capacity (CUPRAC), and ferric reducing power (FRAP). Anxiety and depression measures were used to measure psychological distress. Men exhibited a higher antioxidant status (lower oxidative stress) than women, and higher antioxidant capacity was associated with fewer sleep impairments (β = -0.43). Psychological distress may increase sleep impairment (β = -0.26). Furthermore, older individuals experienced less sleep impairment (β = -0.27), while sex had minimal influence on sleep deterioration, although it appears that men had fewer disturbances (β = -0.12). Having a higher antioxidant status, lower psychological distress, being male, and being older seem to act as predictors of reduced sleep impairment in ALS. Specifically, these four predictors account for 32% of sleep deterioration.Clínical trial registration: The present descriptive, quantitative, cross-sectional study was part of a clinical trial involving ALS patients, registered under the number NCT04654689 ( https://clinicaltrials.gov/study/NCT04654689#wrapper ).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.